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Abstract: Background: Spinocerebellar ataxia type 1 (SCA-ATXN1) is an inherited progressive ataxia disorder
characterized by an adult-onset cerebellar syndrome combined with nonataxia signs. Retinal or optic nerve
affection are not systematically described.
Objectives: To describe a retinal phenotype and its functional relevance in SCA-ATXN1.
Methods: We applied optical coherence tomography (OCT) in 20 index cases with SCA-ATXN1 and 22 healthy
controls (HCs), investigating qualitative changes and quantifying the peripapillary retinal nerve fiber layer
(pRNFL) thickness and combined ganglion cell and inner plexiform layer (GCIP) volume as markers of optic
atrophy and outer retinal layers as markers of maculopathy. Visual function was assessed by high- (HC-VA) and
low-contrast visual acuity (LC-VA) and the Hardy-Rand-Rittler pseudoisochromatic test for color vision.
Results: Five patients (25%) showed distinct maculopathies in the ellipsoid zone (EZ). Furthermore, pRNFL
(P < 0.001) and GCIP (P = 0.002) were reduced in patients (pRNFL, 80.86  9.49 μm; GCIP, 1.84  0.16 mm3)
compared with HCs (pRNFL, 97.02  8.34 μm; GCIP, 1.98  0.12 mm3). Outer macular layers were similar
between groups, but reduced in patients with maculopathies. HC-VA (P = 0.002) and LC-VA (P < 0.001) were
reduced in patients (HC-VA [logMAR]: 0.01  010; LC-VA [logMAR]: 0.44  0.16) compared with HCs (HC-VA
[logMAR]: –0.12  0.08; LC-VA [logMAR]: 0.25  0.05). Color vision was abnormal in 2 patients with
maculopathies.
Conclusions: A distinct maculopathy, termed EZ disruption, as well as optic atrophy add to the known nonataxia
features in SCA-ATXN1. Whereas optic atrophy may be understood as part of a widespread neurodegeneration,
EZ disruption may be explained by effects of ataxin-1 gene or protein on photoreceptors. Our findings extend
the spectrum of nonataxia signs in SCA-ATXN1 with potential relevance for diagnosis and monitoring.
Spinocerebellar ataxia type one (SCA-ATXN1 in revised nomen-
clature, formerly SCA1) is a dominantly inherited autosomal
progressive ataxia disorder caused by translated CAG-repeat expan-
sions in the ataxin 1 gene (ATXN1).1–3 The elongated ATXN1
protein seems to be not only neurotoxic itself, but several conserved
sequence motifs in the ATXN1 protein indicate a role of ATXN1
as a regulator of transcription and RNA processing, suggesting
widespread pathological consequences in SCA-ATXN1.4 Clinically,
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SCA-ATXN1 is typically characterized by an adult-onset cerebellar
syndrome, which is typically combined with nonataxia signs.5,6
These include most prominently pyramidal signs, but also comprise
brainstem oculomotor signs, autonomic dysfunction, late cognitive
impairment, and a variety of movement disorders, such as chorea,
dystonia, myoclonus, and tremor.7–10 Retinal or optic nerve
affection are well-established clinical characteristics of several spi-
nocerebellar ataxias, such as spinocerebellar ataxia type
7 (SCA-ATXN7), but not yet described in SCA-ATXN1.11,12
However, a few incidental case series and smaller studies suggest ret-
inal neuroaxonal degeneration or report a potentially distinct
maculopathy, including photoreceptor alterations, and a decline of
visual function in a subset of SCA-ATXN1 patients.13,14 This is
further sustained by drosophila animal models of SCA-ATXN1
suggesting retinal neurodegeneration.15
Against this background, we aimed to investigate neu-
rodegeneration of retina and optic nerve, macular anomalies, and
their functional relevance in a cross-sectional cohort of 20 index
cases with SCA-ATXN1.
Methods
Study Sample
Twenty patients with genetically confirmed and manifest
SCA1-ATXN1 were prospectively recruited between June 2010
and November 2016 for this cross-sectional observational study
from one university ataxia clinic (Charité–Universitätsmedizin Ber-
lin, Berlin, Germany) and examined at the NeuroCure Clinical
Research Center (NCRC). The inclusion criterion was genetically
confirmed diagnosis of SCA1-ATXN1. Exclusion criteria for this
analysis included missing retinal optical coherence tomography
(OCT) data. Two patients and three eyes in 2 other patients had
OCT of insufficient image quality and were excluded from the sta-
tistical (but not from the descriptive) analysis. Nine patients (45%)
were previously published in a smaller cohort study by Stricker
et al., which reported OCT findings from an earlier time point.14
Number of CAG-repeats, Scale for the Assessment and Rating of
Ataxia (SARA) score16 within 90 days of the OCT examination
and time since onset of permanent gait ataxia were accessible in the
clinical database for 16, 15, and 20 patients, respectively (Table 1).
TABLE 1 Demographic overview for patients with SCA-ATXN1
and age- and sex-matched HCs
HCs SCA-ATXN1
Subjects [N] 22 20
Age [years, mean  SD] 47.5  13.4 45.10  12.37
Sex [female, N (%)] 11 (50) 9 (45)
SARA score [median
(IQR)]; n = 15
— 15 (11, 17)
Time since onset
[years, median
(IQR)]; n = 20
— 8.5 (4.3, 11.3)
No. of CAG repeats
(expanded allele)
[median (IQR)]; n = 16
— 49.5 (46, 53)
IQR, interquartile range; N, number; SD, standard deviation.
TABLE 2 Case description for SCA-ATXN1 patients with EZ disruption
Demographics
Description of Macular
Abnormality Eye OCT Metrics Visual Function
1 Age 52 y
Disease duration 5 to 10 y
SARA score 16.0
Foveal EZ disruption OD GCIP 1.93 mm3
ELM 0.47 mm3
EZ 0.78 mm3
HC-VA 0.00
LC-VA 0.495
HRR Abnormal
OS GCIP 1.96 mm3
ELM 0.47 mm3
EZ 0.74 mm3
HC-VA 0.00
LC-VA 0.602
HRR Abnormal
2 Age 51 y
Disease duration >10 y
SARA score 6.0
Foveal EZ disruption OD Excluded from
quantitative analyses
HC-VA 0.201
LC-VA 0.796
HRR Abnormal
OS HC-VA 0.00
LC-VA 0.495
HRR normal
3 Age 45 y
Disease duration >10 y
SARA score 14.5
Incipient foveal EZ
disruption
OD GCIP 1.78 mm3
ELM 0.50 mm3
EZ 0.82 mm3
HC-VA –0.097
LC-VA 0.301
HRR Normal
OS GCIP 1.76 mm3
ELM 0.48 mm3
EZ 0.82 mm3
HC-VA –0.097
LC-VA 0.398
HRR Normal
4 Age 54 y
Disease duration 5 to 10 y
SARA score 15.0
Temporal EZ disruption
and drusen
OD GCIP 1.70 mm3
ELM 0.45 mm3
EZ 0.88 mm3
HC-VA 0.00
LC-VA 0.699
HRR NA
OS Excluded from
quantitative analyses
HC-VA 0.201
LC-VA 0.921
HRR NA
5 Age 35 y
Disease duration < 5 y
SARA score 9.0
Temporal EZ disruption,
interrupted RPE
contour, RPE defect
OD Excluded from
quantitative analyses
NA
N, number; NA, not available; OD, right eye; OS, left eye.
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Apart from the ataxia rating, a description of eye movements was
available for 20 patients, from which 19 (95%) presented with
abnormalities: 16 patients (80%) with saccadic pursuit, 10 patients
(50%) with slowing of saccades, 11 patients (55%) with failure of
fixation suppression in testing of the vestibular-ocular reflex,
7 patients (35%) with hypo- or hypermetric saccades, and 3 patients
(15%) with a gazed-evoked nystagmus.
For comparison, we included cross-sectional data of 22 healthy
controls (HCs) from the NCRC’s normative OCT database mat-
ched for sex (χ2 < 0.001; P > 0.999) and age (W = 200; P = 0.600).
Best-corrected high-contrast monocular visual acuity (HC-VA) and
2.5% low-contrast visual acuity (LC-VA), using retroilluminated
Early Treatment in Diabetes Retinopathy Study (ETDRS) at 4 m
distance and Sloan charts at 2 m distance, respectively, (Precision
Vision, Woodstock, IL) as well as monocular color vision assessments
applying the Hardy-Rand-Rittler pseudoisochromatic test (HRR)
were acquired in 12 patients and 5 HCs. The study was approved by
the local ethics committee of Charité–Universitätsmedizin Berlin
(EA1/17515) and conducted in accordance with the applicable
German laws and the current version of the Declaration of Helsinki.
All participants gave written informed consent. All data is reported
according to STROBE reporting guidelines.
OCT
The same Spectralis SD-OCT machine (Heidelberg Engineering,
Heidelberg, Germany) with automatic real-time (ART) function
for image averaging was used in all participants.17 Qualitative OCT
analysis was performed by an experienced ophthalmologist (O.Z.).
Total macular volume (TMV) and all intraretinal layers (macular
retinal nerve fiber layer; mRNFL), combined ganglion cell and
inner plexiform layer (GCIP), inner nuclear layer (INL), outer
plexiform layer (OPL), outer nuclear layer and external limiting
membrane (ONL), combined external limiting membrane and
ellipsoid zone (ELM/EZ), external limiting membrane (ELM),
ellipsoid zone (EZ), retinal pigment epithelium (RPE), combined
outer layers (OL; OPL to RPE) were calculated as a 6-mm-
diameter cylinder around the fovea from a macular volume scan
(25 × 30 degrees, 61 vertical B-scan). Peripapillary retinal nerve
fiber layer thickness (pRNFL) was measured with an activated eye
tracker using a ring scan around the optic nerve head (12 degrees,
FIG. 1. Examples of macular anomalies found in qualitative OCT
analyses for SCA-ATXN1 patients in table 3 for right eye
(OD) and left eye (OS).
TABLE 3 Intraretinal layer quantification by OCT and visual acuity assessment in patients with SCA-ATXN1 and HCs
HCs [Mean  SD] SCA-ATXN1 [Mean  SD]
HC Versus SCA-ATXN1
B SE P Value
OCT data
pRNFL [μm] 97.02  8.34 80.86  9.49 –16.17 3.13 2.4•10–7
TMV [mm3] 8.70  0.33 8.50  0.46 –0.199 0.144 0.170
mRNFL [mm3] 1.09  0.08 1.07  0.14 –0.021 0.039 0.600
GCIP [mm3] 1.98  0.12 1.84  0.16 –0.144 0.047 0.002
INL [mm3] 0.99  0.07 1.00  0.09 0.015 0.025 0.560
OL [mm3] 4.64  0.20 4.55  0.36 –0.097 0.111 0.380
OPL [mm3] 0.70  0.05 0.70  0.04 0.005 0.014 0.710
ONL [mm3] 1.69  0.15 1.63  0.24 –0.070 0.067 0.330
ELM/EZ [mm3] 1.30  0.05 1.31  0.06 0.008 0.017 0.620
ELM [mm3] 0.49  0.02 0.48  0.02 –0.008 0.007 0.250
EZ [mm3] 0.81  0.04 0.83  0.05 0.017 0.014 0.220
RPE [mm3] 0.96  0.04 0.83  0.05 –0.032 0.022 0.150
Visual acuity data
HC-VA [logMAR]; n = 12 –0.12  0.08 0.01  0.10 0.134 0.040 0.001
LC-VA [logMAR]; n = 12 0.25  0.05 0.44  0.16 0.185 0.046 6.0•10–5
IQR, interquartile range; N, number; OL, outer layers (OPL, ONL, ELM, EZ, and RPE); SD, standard deviation.
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1536 A-scans) or the most inner 3.5-mm ring of a star-and-ring
scan around the optic nerve head (12 degrees, 768 A-scans). For
patients, 21 ring scans and 28 macular scans were included for the
quantitative OCT analysis after exclusions because of insufficient
quality.18,19 Segmentation of all layers was performed automatically
and corrected, if necessary, by experienced raters (F.C.O. for SCA-
ATXN1, S.M. for HCs) using an in-house–developed software20
based on a segmentation algorithm by Lang et al.21 for macular scan
and a software provided by the OCT manufacturer (Eye Explorer
1.9.10.0 with viewing module 6.3.4.0; Heidelberg Engineering)
for ring scans. OCT data are reported according to the APOSTEL
recommendations.22 Clear generalized cut-off values for pathologi-
cal macular layer thinning are not yet established.
Statistical Analyses
Group differences in age and sex between SCA-ATXN1 and
HCs were tested by χ2 and Wilcoxon rank-sum tests, respectively.
Group differences for OCT parameters and visual acuity assess-
ments as well as correlations with clinical metrics were analyzed
by generalized estimating equation models to account for within-
patient intereye associations of monocular measurements. All tests
and graphical representations were performed with R software
(V3.3.1; R Foundation for Statistical Computing, Vienna,
Austria).23 Statistical significance was established at P < 0.05.
Because of the exploratory character of our analyses, we refrained
from corrections for multiple comparison.
FIG. 2. Box plots for selected OCT results in SCA-ATXN1 (blue) and HC (gray). Patients with EZ disruption displayed as larger dots. n.s., not
significant.
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Data Availability
Data not provided in the article will be shared at the request of
other investigators for purposes of replicating procedures and
results.
Results
We found pathological disruption of EZ in 5 patients (25%;
Table 2; Fig. 1). Two further patients (10%) had unspecific
abnormalities (floaters, monocular epiretinal gliosis of the
papillomacular bundle). The disruption of EZ was pronounced
in the foveal and parafoveal area of 2 patients (Table 2; Fig. 1,
Patients 1 and 2), less pronounced in the fovea of 1 patient
(Table 2; Fig. 1, Patient 3), and more temporally located and less
pronounced in 2 patients (Table 2; Fig. 1, Patients 4 and 5).
HRR indicated an abnormal color vision in 2 patients with EZ
disruption showing a mild red-green deficiency binocularly in
the first patient and monocularly in the second patient.
We then analyzed group differences in neuroretinal content
between eyes from patients with SCA-ATXN1, including those
with macular anomalies, and HCs (Table 3; Fig. 2). pRNFL as
the marker of axonal content in SCA-ATXN1 was reduced
compared with HCs. Compared with the device-specific control
database, 57% (N = 12) of eyes had pRNFL values within nor-
mal limits; for 19% (N = 4) of eyes, pRNFL values were border-
line below, and 24% (N = 5) had pRNFL values below normal
limits. Also, GCIP as a marker of ganglion cell volume was lower
in SCA-ATXN1 compared with HCs. In contrast, INL and
outer retinal layers were similar between SCA-ATXN1 and HCs
(Table 3; Fig. 2). The 5 patients with disruption of EZ did visu-
ally not show signs of more pronounced retinal neuroaxonal loss
(Table 2). We restrained from further statistical analysis because
of the small and highly unbalanced subsets. HC-VA as well as
LC-VA were reduced in patients with SCA-ATXN1 compared
with HCs (Table 3; Fig. 2). Because of the low sample size, we
refrained from performing a statistical subgroup analysis and
structure-function correlations.
In SCA-ATXN1 patients, time since onset showed a positive
correlation with GCIP (B = 0.012; standard error [SE] = 0.005;
P = 0.014), but not pRNFL (B = 0.480; SE = 0.424;
P = 0.260). Furthermore, disease severity measured by SARA
score was correlated neither with pRNFL (B = 0.099;
SE = 0.483; P = 0.840) nor with GCIP (B = –0.001; SE = 0.006;
P = 0.830). Number of CAG repeats (expanded allele) were not
correlated with pRNFL nor GCIP.
Discussion
In our study, 25% of patients with SCA-ATXN1 displayed a
distinct macular pathology, a disruption of the EZ, suggesting a
retinal involvement in this disease. Furthermore, SCA-ATXN1
patients presented with findings (pRNFL and macular GCIP loss)
consistent with optic atrophy, which are pointing toward a neu-
rodegenerative process in the optic nerve. Together with the
reported visual function impairment, these structural changes
should be considered as further nonataxia signs in SCA-ATXN1.
The macular pathologies reported here are in line with three
previously published cases.24–26 Saito et al. described an
SCA-ATXN1 patient with RPE reduction in fundus examina-
tion, subsequently reduced HC-VA, and loss of color vision and
classified the changes as pigmentary macular dystrophy similar to
the alterations observed in SCA7.25 Vaclavik et al. described
hypopigmented macular RPE and a loss of photoreceptors with
a subsequent central depression of electrical potentials in
2 patients using OCT and multifocal electroretinogram.26
Lebranchu et al. described altered foveal lamination and abnor-
mal spacing between RPE and external limiting membrane in
4 patients.24 Despite different terminology and discrepancies in
examination methods, provided images in combination with
descriptions highly suggest that the case reports and our study all
report on the same macular pathology.
It is possible that the macular pathology is caused by a yet
unrecognized pleiotropic effect of mutant atxn1 on photorecep-
tors. Pathophysiological evidence for this was contributed by
Fernandez-Funez et al., who induced the expression of polyQ-
expanded ATXN1 in retinae of drosophila, which subsequently
developed a progressive elimination of retinal cell bodies and
axonal projections.15 In this drosophila study, phenotype severity
was correlated with the expression level of mutant protein.15 In
our study, EZ disruption was not associated with disease severity
or pronounced retinal neurodegeneration, which may simply be
a matter of sample size. Alternatively, development of
maculopathy may be independent of optic atrophy in
SCA-ATXN1, which may be attributed to cell-specific tran-
scriptional effects of expanded ATXN1. Multiple genes associ-
ated with macular disease are located in 6p21.1, for example the
genes peripherin-2, which is critical for photoreceptor formation
and maintenance, and guanyulate cyclase activator 1a, a causal
gene for cone dystrophy.24,27,28 To differentiate a potential causal
effect of the CAG-repeat expansion on 6p23 from a nearby
accompanying mutation, a gene analyses of the respective loci in
affected patients would be necessary in the future.
Next to this first systematic description of the novel ellipsoid
zone disruption maculopathy, our results solidify previous reports
on optic nerve atrophy as part of the clinical picture of
SCA-ATXN1 showing pRNFL and GCIP, but not mRNFL,
thinning. Of note, mRNFL is very thin and has a high intertest
variability, making a significant group difference in a small sample
unlikely.20,29 Abe et al., in 1997, first reported that SCA-ATXN1
patients showed optic nerve atrophy by fundus examination as well
as color vision dysfunction and visual field abnormalities.30 An ear-
lier study from our group in 2011,14 a study comprising several
SCA genotypes by Pula et al.,13 and a recent case series by
Nishiguchi et al.31 reported temporal RNFL thinning and macular
neurodegeneration, respectively. The neuroaxonal damage might
point toward concomitant optic neuropathy as part of a central ner-
vous system degeneration in SCA-ATXN1.32 However, data from
longitudinal studies and from nonmanifest carriers are necessary to
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chronologically interpret retinal neurodegeneration during the dis-
ease process. To date, it remains unclear whether retinal changes
are detectable in premanifest stages of disease as has been shown for
some clinical and brain imaging markers.33
The reported changes resulted in impaired visual function in
our study—with visual acuity decline as well as with color vision
deficits in patients with EZ disruption. The magnitude of
changes suggest that they are clinically meaningful, and at least
the color vision deficits could probably be detected in clinical
visual assessments using standard procedures such as Ishihara
charts.34 Whereas the overall limited number of cases with mac-
ular pathologies preclude further analyses regarding the origin of
dysfunction, the reduced visual acuity could suggest a relevance
of optic atrophy for visual acuity loss. Conversely, 2 patients
were suggestive of color vision deficiencies, and these 2 patients
also presented with macular phenotype. This is further supported
by the aforementioned case reports, also reporting, in part, color
vision deficits.24,25,30
Given the rarity of SCA-ATXN1, an important strength of
the study is the comparably large sample size. However, the sta-
tistical power might have still been insufficient to confirm
numerical differences in outer layers where low measurements in
eyes with EZ disruption suggest a potential degenerative rele-
vance. Further important limitations of our study include the
incomplete clinical and functional (especially visual function) data
and the lack of blue autofluorescence and longitudinal data to
conclusively confirm a progressive retinal neurodegeneration in
SCA-ATXN1. Especially, investigations in nonmanifest carriers
would be of high interest in this respect.
Our findings extend the previously established spectrum of
nonataxia signs in SCA-ATXN1 with potential relevance for
diagnosis and monitoring. Within the scope of the proposed
diagnostic algorithm by Rossi et al.,35 the ellipsoid zone disrup-
tion maculopathy may be indicative of an SCA-ATXN1 diagno-
sis. However, additional research is needed to consolidate this
notion, especially at disease onset when differential diagnosis is
most relevant, and in comparison to other ataxias, both of which
were not within the scope of our current study. With 25% of
patients presenting with distinct macular changes—a disruption
of the EZ—this macroscopic phenotype appears frequently
enough to be considered during clinical workup. The reported
changes were associated with visual dysfunction, and thus explo-
ration and examination of the visual system should be part of
patient counseling in SCA-ATXN1. If confirmed in a longitudi-
nal study, neurodegeneration of the afferent visual system mea-
sured by OCT may be used as a sensitive and easily accessible
marker of global neurodegeneration in SCA-ATXN1 and—in
the light of approaching therapeutic candidates—even serve as
outcome candidate for clinical trials.4,36
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